Drug
Carboplatin clinical trials
Also written Paraplatin, NSC-241240, Carboplatinum and BMY-26575.
Related medicines add 1 study
Counted the way a researcher would: Carboplatin with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Carboplatin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Carboplatin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Mar 1989 · PARAPLATIN · NDA 019880 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
1,215 studies that test it; most in 2006 (61); 3 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1991 | 2 |
| 1992 | 1 |
| 1993 | 2 |
| 1994 | 4 |
| 1995 | 2 |
| 1996 | 11 |
| 1997 | 17 |
| 1998 | 36 |
| 1999 | 36 |
| 2000 | 35 |
| 2001 | 36 |
| 2002 | 36 |
| 2003 | 52 |
| 2004 | 59 |
| 2005 | 57 |
| 2006 | 61 |
| 2007 | 51 |
| 2008 | 59 |
| 2009 | 51 |
| 2010 | 53 |
| 2011 | 42 |
| 2012 | 32 |
| 2013 | 34 |
| 2014 | 39 |
| 2015 | 44 |
| 2016 | 32 |
| 2017 | 38 |
| 2018 | 26 |
| 2019 | 46 |
| 2020 | 32 |
| 2021 | 37 |
| 2022 | 33 |
| 2023 | 27 |
| 2024 | 36 |
| 2025 | 33 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 184 · Other 1,044
National Cancer Institute (NCI) (55) · M.D. Anderson Cancer Center (38) · Children's Oncology Group (34) · Eli Lilly and Company (30) · Alliance for Clinical Trials in Oncology (29) · SCRI Development Innovations, LLC (28) · Memorial Sloan Kettering Cancer Center (23) · SWOG Cancer Research Network (16)
Often tested with
Tested in the same studies.
Paclitaxel (523) · Etoposide (154) · Cisplatin (136) · Gemcitabine (115) · Pemetrexed (112) · Bevacizumab (110) · Docetaxel (104) · Cyclophosphamide (85)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 86 phase 3 studies under way
Carboplatin is the comparator. A study of two new drugs counts under both.
- 8Izalontamab brengitecan · Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd. · next primary completion Mar 2028
- 5Sacituzumab tirumotecan · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Merck Sharp & Dohme LLC · next primary completion Dec 2026
- 5Durvalumab · AstraZeneca · next primary completion Jul 2027
- 5Sacituzumab govitecan · Gilead Sciences, GBG Forschungs GmbH · next primary completion Feb 2027
- 4Datopotamab deruxtecan · AstraZeneca · next primary completion Jul 2027
- 3Tremelimumab · AstraZeneca
- 3Disitamab vedotin · Seagen, a wholly owned subsidiary of Pfizer, Peking University First Hospital · next primary completion Dec 2026
- 3Pembrolizumab · Astellas Pharma Global Development, Inc., Merck Sharp & Dohme LLC · next primary completion May 2027
Reaching primary completion within a year · 65, 13 in phase 3
Studies that test Carboplatin, phase 3 first.
- Nov 2026High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Phase 3 · Gustave Roussy, Cancer Campus, Grand Paris
- Nov 2026A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast CancerPhase 3 · Tata Memorial Hospital
- Dec 2026Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCPhase 3 · Stanford University
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Dec 2026A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung CancerPhase 3 · Mabscale, LLC
- Dec 2026Paediatric Hepatic International Tumour TrialPhase 3 · University of Birmingham
- Jan 2027A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 3 · AstraZeneca
- Mar 2027Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast CancerPhase 3 · Shanghai Jiao Tong University School of Medicine
- Jun 2027Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking SurgeryPhase 3 · ARCAGY/ GINECO GROUP
- Jun 2027A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/3 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses Carboplatin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,228
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Carboplatin
- Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNot yet recruitingPhase 2Kevin ContreraNCT07932067Written as Cisplatin or carboplatin
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Carboplatin
- Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response GenesRecruitingPhase 3Canadian Cancer Trials GroupNCT06439225Written as Carboplatin
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyRecruitingPhase 3Boehringer IngelheimNCT07472517Written as carboplatin
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07061977Written as Carboplatin
- Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal CancerRecruitingPhase 2Dustin DemingNCT06493019Written as Carboplatin
- Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsRecruitingPhase 2Guangzhou University of Traditional Chinese MedicineNCT07709585Written as Pemetrexed + Cisplatin /Carboplatin
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Carboplatin
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Carboplatin
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Carboplatin
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%RecruitingPhase 2Swiss Cancer InstituteNCT07020065Written as Carboplatin
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT07195734Written as Carboplatin
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingPhase 2New York Medical CollegeNCT02393157Written as Carboplatin
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Carboplatin
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Carboplatin
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingPhase 2AbbVieNCT06890338Written as Carboplatin
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07860450Written as Carboplatin and paclitaxel
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as Carboplatin (AUC 5)
- A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingPhase 2Medical University of South CarolinaNCT07743190Written as Carboplatin
See all 1,228 studies that test Carboplatin →
Given beside what is tested · 1,352 — Carboplatin is usual care or a partner of the new treatment
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Carboplatin
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Carboplatin
- Chemotherapy With or Without Immunotherapy for Peritoneal MesotheliomaRecruitingPhase 2National Cancer Institute (NCI)NCT05001880Written as Carboplatin
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Carboplatin
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Carboplatin
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06797635Written as Carboplatin
- Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 1/2ImunonNCT05739981Written as Carboplatin
- Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT05019716Written as Carboplatin
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Carboplatin
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingPhase 3ImunonNCT06915025Written as Carboplatin
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungRecruitingPhase 2/3National Cancer Institute (NCI)NCT05058651Written as Carboplatin
- A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) MutationRecruitingPhase 1Kestrel Therapeutics, Inc.NCT07458347Written as Carboplatin
- A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07221474Written as Carboplatin
- BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)RecruitingPhase 3SystImmune Inc.NCT07625644Written as Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 3RemeGen Co., Ltd.NCT07829549Written as RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2ExelixisNCT07845786Written as Carboplatin
- Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingPhase 2Medical University of South CarolinaNCT07720167Written as Carboplatin
- A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RecruitingPhase 3Bristol-Myers SquibbNCT06646276Written as Carboplatin
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06966700Written as Carboplatin
- A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06952504Written as Carboplatin
Showing 20 of 1,352.
As the comparator · 192 — what is tested is compared with Carboplatin
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Carboplatin
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT04671667Written as Carboplatin
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruitingPhase 3National Cancer Institute (NCI)NCT04166409Written as Carboplatin
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07190248Written as Carboplatin
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingPhase 2/3Bristol-Myers SquibbNCT07100080Written as Carboplatin
- A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739199Written as Carboplatin
- A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)RecruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07739186Written as Carboplatin
- Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic AlterationsRecruitingPhase 3RemeGen Co., Ltd.NCT07829549Written as RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Carboplatin
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790Written as Carboplatin
- A Study of DS-3939a in Participants With Solid TumorsRecruitingPhase 1/2Daiichi SankyoNCT07739966Written as Carboplatin
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Carboplatin
- Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07504588Written as Carboplatin
- A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07227597Written as Carboplatin
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3Hoffmann-La RocheNCT06793215Written as Carboplatin
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 3BayerNCT06452277Written as Carboplatin
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as Carboplatin
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Carboplatin
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07043725Written as Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126Written as paclitaxel plus carboplatin
Showing 20 of 192.
What changed recently
From the registry's own updates since Oct 16, 2026.
Started recruiting1
Newly registered3
- Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck CancerNov 12, 2026NCT07932067
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Oct 16, 2026NCT07877584
Codes
What other systems call Carboplatin · ClinicalTrials.gg INT008516
- MeSH (NLM) D016190CarboplatinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BG3F62OND5CARBOPLATINConfirmed FDA, NLM, Wikidata
- RxNorm 40048Confirmed FDA, Wikidata
- Wikidata Q415588carboplatinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1282CarboplatinConfirmed FDA, Wikidata
- DrugBank DB00958One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D016190 | Carboplatin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BG3F62OND5 | CARBOPLATIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 40048 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415588 | carboplatin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1282 | Carboplatin | Confirmed FDA, Wikidata |
| DrugBank | DB00958 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.